NewAmsterdam Pharma Company N.V. Warrant
NAMSWStock
$20.56+243.61%52W
Market Cap—
P/E—
Div yield—
Beta6.93
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-36.86%
Price vs S&P 500 (4W)-10.42%
VGM Score74.07
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NAMSWNewAmsterdam Pharma Company N.V. Warrant | — | — | B | $20.56 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
NewAmsterdam Pharma is a late-stage biopharmaceutical company developing therapies for cardio-metabolic diseases. Its lead product, obicetrapib, is an oral CETP inhibitor designed to overcome the efficacy and tolerability limitations of current LDL cholesterol-lowering treatments in patients with inadequate response or poor tolerance to existing therapies.